Cantor Fitzgerald upgraded Denali Therapeutics (DNLI) to Overweight from Neutral. Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your ...

Cantor Fitzgerald analyst Josh Schimmer upgraded Denali Therapeutics (DNLI) to Overweight from Neutral without a price target Shares are down ...

Denali Therapeutics vice president of clinical manufacturing Leah Frautschy, center, cuts a ribbon opening Denali Therapeutics' new biomedical facility in Salt Lake City on Thursday, March 27, 2025.

Denali Therapeutics Inc. has a one year low of $10.57 and a one year high of $33.33. Denali Therapeutics ( NASDAQ:DNLI – Get Free Report ) last announced its quarterly earnings data on Thursday ...

Cantor Fitzgerald upgraded shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) from a neutral rating to an overweight rating in a report issued on Thursday morning, MarketBeat Ratings reports.

SALT LAKE CITY — Denali Therapeutics is advancing the fight against neurodegenerative diseases thanks to pioneering work in methods to carry medicines across the blood-brain barrier, a critical ...

A 12-year, $1.5 billion push to develop drugs for rare genetic diseases led Denali Therapeutics Inc. to ask regulators Wednesday to approve its first drug, a treatment for a rare, life-shortening ...

Get the next trade alert free. Denali Therapeutics, Inc. DNLI shares traded higher on Wednesday after the company initiated its biologics license application (BLA) for the accelerated approval of ...

SOUTH SAN FRANCISCO - Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company with a market capitalization of $1.8 billion, has initiated a rolling submission for a biologics license ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...